Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
----------
AIM - WINNERS
----------
Eurasia Mining PLC, up 30% at 11.18 pence, 12-month range 8.50p-39.90p. The Russia-focused mining and mineral exploration company confirms there has been no detrimental effect from Russia sanctions on its operations and activities. Eurasia says it has no bank accounts or relationship with Russian state-owned banks. Its production is sold in the domestic market at prices fixed in dollars, while the costs are mainly fixed in roubles. As such, it highlights a weak rouble helps its bottom line.
----------
Tintra PLC, up 18% at 188.80p, 12-month range 29.00p-375.00p. The investment and advisory firm says the sale of its lottery administration business to Sterling Management Centre Ltd is moving into its final stage. Tintra says that regulatory and administrative issues related to the transaction have been addressed and that both the board and the buyer are confident that the transaction will be completed in a timely fashion.
----------
Revolution Beauty Group PLC, up 5.4% at 127.50p, 12-month range 95.18p-173.00p. The beauty products retailer acquires US cosmetics brand BH Cosmetics Holdings LLC for USD3.9 million. The acquisition is financed through existing cash resources.
----------
AIM - LOSERS
----------
Braveheart Investment Group PLC, down 12% at 14.90p, 12-month range 11.10p-130.95p. The investor in small-and medium-sized businesses says sale of Paraytec Ltd at an acceptable price now seems unlikely. Says UK government's decision to rapidly wind down the testing and isolation requirements for UK citizens and travellers to the UK has abruptly changed the nature of the Covid-19 test market. This has led to a slowing of discussions with the remaining potential acquirers of Paraytec and its Covid-19 test. Braveheart says it now looks unlikely that it will be able to conclude a sale with one of the remaining parties at an acceptable price in the foreseeable future. Paraytec should focus on the development of the sepsis and bladder cancer applications for its technology, it adds.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.